RCT | Sulbactam-durlobactam non-inferior to colistin in reducing 28-day mortality from carbapenem-resistant ABC

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) – The Lancet Infectious Diseases (link to abstract – $ for full-text)

News Release: Novel antibiotic succeeds in trial against hospital-acquired pneumonia – Rutgers University